solid tumors
Conditions
Interventions
Solid tumor patients receiving treatment with adebelimab:NA
Sponsors
Dingyuan General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Subjects voluntarily joined the study, signed the informed consent form, complied well, and cooperated with the visit; 2. Age >=18 years (calculated based on the day informed consent was signed); 3. Subjects with advanced malignant tumors confirmed by clinical diagnostic criteria or histopathological/cytological examination who have progressed after receiving previous systemic treatment; 4. ECOG is 0 - 2; 5. The functions of important organs meet the following requirements: 1) Absolute neutrophil count >=1.5×10^9/L or absolute leukocyte count >=3.5×10^9/L; 2) Platelet >=100×10^9/L; 3) Hemoglobin >=90g/L; 4) Serum albumin >= 3 g/dL; 5) Total bilirubin =50mL/min;
Exclusion criteria
Exclusion criteria: 1. Subjects with allergies or hypersensitivity to therapeutic drugs, and subjects with autoimmune diseases; 2. Treatment with steroids for more than 50 days, or requiring long-term steroid use; 3. Uncontrolled symptomatic brain metastases or mental abnormalities who cannot correctly express subjective symptoms; 4. Pregnant or lactating women who are fertile but refuse to use contraceptive measures; 5. Persons with serious heart disease or history, including: documented history of congestive heart failure, high-risk uncontrollable arrhythmia, angina requiring medication, clinically clear heart valve disease, history of severe myocardial infarction, and refractory hypertension; 6. Having received allogeneic tissue/solid organ transplantation; 7. According to the investigator's judgment, there are serious concomitant diseases that endanger the safety of the subject or affect the subject's completion of the study (such as hypertension, diabetes, thyroid disease, etc. that are not clinically controlled); 8.Other circumstances that the investigator determines are not suitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival;overall survival;objective response rate;disease control rate;duration of response; | — |
Countries
China
Contacts
Public ContactJing Yan
Dingyuan General Hospital
Outcome results
None listed